In this video, Michael J. Bloch, MD, reviews and discusses a recently published study on the association of menstrual cycle regularity and length with cardiovascular diseases, including how the results...
In this video, Zeenat Safdar, MD, MS, a STELLAR trial investigator, discusses the STELLAR trial results, which supported the FDA approval of sotatercept. Sotatercept is the first activin signaling inhibitor...
In this video, Maura Marcucci, MD, MSc, discusses her study's surprising results, which showed no differences between hypotension-avoidance and hypertension-avoidance strategies for decreasing adverse...
Steven E. Nissen, MD, lead author of the study “Bempedoic Acid And Cardiovascular Outcomes In Statin-Intolerant Patients,” answers questions on the importance of his team’s research on bempedoic acid, how...
In this video, Matthew C. Tattersall, DO, MS, discusses persistent asthma and its association with carotid plaque burden, which is a strong predictor of atherosclerotic cardiovascular disease events, in the...
In this commentary, Michael J. Bloch, MD, and Evan Bloch discuss the optimal approach to managing patients with hypertension in the United States, including using patients' self-measured blood pressure and...
In this article, Michael J Bloch, MD, discusses the usage of RAS-blocking agents, slowing the progression of end-stage renal disease, and reducing cardiovascular events in patients with advanced kidney...
03/05/2024
Multidisciplinary Dialogue: Clinical Rounds and Case Reviews, Ep. 15
Multidisciplinary Dialogue: Clinical Rounds and Case Reviews, Ep. 15
In this podcast, Anil Harrison, MD, and Paul Shiu, DO, discuss how to evaluate a patient with newly diagnosed hypertension, pharmacological and non-pharmacological interventions available for patients...
In this podcast, Alan S. Go, MD, discusses the results of his recent study, which examined the relationship between HIV, heart failure, and patient demographics.
In this article, Michael Bloch, MD, and Evan Bloch discuss findings from the SELECT trial, including the use of the glucagon-like peptide 1 receptor agonist, semaglutide, to reduce the risk of major...